Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Effervescent suppository for treating mammal vaginitis

A technology for mammals and vaginitis, applied in the directions of suppository delivery, drug combination, medical preparations of inactive ingredients, etc., can solve the problems of unfavorable penetration into the vaginal mucosa, small distribution area of ​​the drug, short retention time, etc., and achieve sterilization effect. Strong, rapid release, convenient administration effect

Active Publication Date: 2014-05-14
昆山博青生物科技有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The technical problem to be solved by the present invention is to provide a kind of biocidal effervescent suppository for mammalian vaginitis, to overcome the inconvenience of using in the prior art. The distribution area of ​​the drug in the vagina is small, the retention time is short, and the interaction with the liquefaction of the mucous membrane is weak, which is not conducive to penetration into the vaginal mucous membrane.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Effervescent suppository for treating mammal vaginitis
  • Effervescent suppository for treating mammal vaginitis
  • Effervescent suppository for treating mammal vaginitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Preparation method 1 of recombinant lysostaphin effervescent suppository (formulation 1)

[0029] 1. Composition and ratio

[0030] Recombinant Lysostaphin 0.01%, Lactose 50%, Microcrystalline Cellulose 30%, Polyoxy 40 Stearate 1%, Povidone 5.99%, Sodium Bicarbonate 5%, Sodium Dihydrogen Phosphate 5%, Micronized Powder Silica gel 3%.

[0031] 2. Preparation

[0032] Weigh 0.01 g of recombinant lysostaphin, 50 g of lactose, 30 g of microcrystalline cellulose, 1 g of polyoxy 40 stearate, 5.99 g of povidone, 5 g of sodium bicarbonate, 5 g of sodium dihydrogen phosphate, and 3 g of micronized silica gel. The above raw materials are crushed through an 80-mesh sieve, mixed evenly, and pressed into a shape.

Embodiment 2

[0033] Example 2 Preparation method 2 of recombinant lysostaphin enzyme effervescent suppository (formulation 2)

[0034] 1. Composition and ratio

[0035] Recombinant Lysostaphin 0.02%, Lactose 20%, Microcrystalline Cellulose 5%, Polyoxy 40 Stearate 9.88%, Povidone 10%, Sodium Bicarbonate 40%, Sodium Dihydrogen Phosphate 15%, Micronized Powder Silica gel 0.1%.

[0036] 2. Preparation

[0037] Weigh 0.02g of recombinant lysostaphin, 20g of lactose, 5g of microcrystalline cellulose, 9.88g of polyoxy 40 stearate, 10g of povidone, 40g of sodium bicarbonate, 15g of sodium dihydrogen phosphate, and 0.1g of micronized silica gel. . The above raw materials are crushed through an 80-mesh sieve, mixed evenly, and pressed into a shape.

Embodiment 3

[0038] Example 3 Preparation method 3 of recombinant lysostaphin effervescent suppository (formulation 3)

[0039] 1. Composition and ratio

[0040] Recombinant Lysostaphin 0.04%, Lactose 10%, Microcrystalline Cellulose 11.96%, Polyoxy 40 Stearate 20%, Povidone 1%, Sodium Bicarbonate 12%, Sodium Dihydrogen Phosphate 40%, Micronized Powder Silica gel 5%.

[0041] 2. Preparation

[0042] Weigh out 0.04 g of recombinant lysostaphin, 10 g of lactose, 11.96 g of microcrystalline cellulose, 20 g of polyoxy 40 stearate, 1 g of povidone, 12 g of sodium bicarbonate, 40 g of sodium dihydrogen phosphate, and 5 g of micronized silica gel. The above raw materials are crushed through an 80-mesh sieve, mixed evenly, and pressed into a shape.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines, and particularly relates to an effervescent suppository for treating mammal vaginitis. A preparation disclosed by the invention consists of the following components in percentage by weight: 0.01-0.04 percent of recombinant lysostaphin, 10-50 percent of lactose, 5-30 percent of microcrystalline cellulose, 1-20 percent of polyoxyl[40]stearate, 1-10 percent of povidone, 5-40 percent of sodium bicarbonate, 5-40 percent of sodium dihydrogen phosphate and 0.1-5 percent of superfine silica powder. The preparation can disintegrate in an effervescent manner in the presence of body fluid after entering the vagina of a mammal, and medicaments are released rapidly by being mixed in foam, so that the contact area between the medicaments and vaginal mucosa is increased, the medicaments can permeate deep into mucosa folds, the acting time of the medicaments on mucosa is prolonged, the local tissue medicament concentration is increased, the treatment effect is enhanced, and various pathogenic bacteria causing vaginitis are killed effectively.

Description

Technical field [0001] The invention relates to a pharmaceutical preparation, in particular to an effervescent suppository for treating vaginitis in mammals. Background technique [0002] Vaginitis in sows is a common and multiple reproductive organ disease in pig production. The main causes of this disease are postpartum vaginal injury, inadequate artificial insemination disinfection, vaginal injury in sows during natural mating, and the passage of pathogenic microorganisms. Vaginitis caused by various ways of infection. Sows suffering from vaginitis will cause reduced lactation or no milk after delivery, so that the piglets cannot get enough milk and affect the growth and development of the piglets. After weaning, sows will not estrus due to vaginal inflammation or repeatedly fail to match after estrus. Even if they are occasionally matched, they will produce weak piglets, stillbirths, mummies or false pregnancies, which will affect the normal performance of sow reproductive p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/47A61K9/02A61K47/38A61P15/02
Inventor 黄青山汪益涵李国栋蒋司嘉
Owner 昆山博青生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com